Full Press Release Details
Enveric Biosciences announced it has signed a nonbinding term sheet to out-license a class of novel psilocin prodrugs to MindBio Therapeutics, an agreement that could yield more than $66 million in sales.
Full Article >>
ENVB Positive Sentiment Score: 75/100
Enveric, MindBio partner to advance psilocin prodrugs for mental health disorders [Healio]
Key Takeaway: Enveric Biosciences has entered into a nonbinding term sheet to out-license novel psilocin prodrugs to MindBio Therapeutics. This partnership is expected to potentially generate over $66 million in sales, indicating a strong market interest in mental health disorder treatments.
Price reaction · baseline $147.852 (2024-05-20 close) · hit pre-market · clean, no other ENVB news in the window
day 0 close
+0.8%
Market Sentiment Analysis
POSITIVE FACTORS
- Enveric has partnered with MindBio to advance innovative treatments.
- The agreement could generate significant revenue exceeding $66 million.
- Focus on psilocin prodrugs highlights potential in mental health therapies.
Frequently Asked Questions
What is the partnership between Enveric and MindBio?
Enveric has signed a nonbinding term sheet to out-license psilocin prodrugs to MindBio.
How much revenue could the agreement generate?
The agreement could yield more than $66 million in sales.
What are psilocin prodrugs used for?
Psilocin prodrugs are being developed for treating mental health disorders.